Sitagliptin

Chemical Name:

Sitagliptin (INN; previously identified as MK-0431 and sold under the trade name Januvia) is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.

SMILES Code: 

O=C(N1CC2=NN=C(C(F)(F)F)N2CC1)C[C@H](N)CC3=CC(F)=C(F)C=C3F.O=P(O)(O)O.[H]O[H]

InChi Code:

InChI=1S/C16H15F6N5O.H3O4P.H2O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4;/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4);1H2/t9-;;/m1../s1

InChi Key:

GQPYTJVDPQTBQC-KLQYNRQASA-N

Keyword:

Sitagliptin,Sitagliptin phosphate,Januvia,Glactiv,ONO-5435, MK-0431, L-000224715, 654671-77-9,654671-78-0, 486460-32-6

Solubility: Soluble in DMSO

Storage: 0 - 4°C for short term (days to weeks), or -20°C for long term (months).

Description: 

Sitagliptin (INN; previously identified as MK-0431 and sold under the trade name Januvia) is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed and is marketed by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The benefit of this medicine is its lower side-effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. Exenatide (Byetta) also works by its effect on the incretin system.

Target: DPP-4